STOCK TITAN

Daxor Corporation - DXR STOCK NEWS

Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.

Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.

The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.

Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.

Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.

In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.

Rhea-AI Summary
Daxor Corporation receives $305K NIH grant for sepsis fluid optimizer development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Daxor Corporation's CEO to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
-
Rhea-AI Summary
Daxor Corporation provides a corporate update on its blood volume measurement technology. They are focused on improving outcomes for patients by solving the problem of accurate blood volume measurement. They have developed a new portable analyzer that can provide results in as little as 15 minutes. They have also received additional funding from the U.S. Department of Defense and National Institutes of Health for further technology development and clinical trials. Daxor continues to expand its commercial adoption and intellectual property portfolio. They reported a 20.64% increase in revenues for their single-use test kits. They have launched a new lab service and anticipate FDA approval for their next-generation analyzer by the end of the year. Daxor has also received a new $1.1 million contract from the U.S. DoD for additional capabilities to their analyzer. They have made progress in clinical outcomes utilizing their blood volume analyzer, with promising results in heart failure patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
Rhea-AI Summary
Daxor Corporation reports an increase in net assets to $30.4 million from $29.0 million. Revenue from diagnostic test kits rose by 20.64% compared to the same period last year. The company secured a $1.1 million contract from the U.S. Department of Defense. The FDA is expected to review the company's next-generation analyzer by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary
Daxor Corporation announces a new research letter validating the benefits of its BVA-100 diagnostic in optimizing therapy for heart failure patients. The study found a statistically insignificant correlation between pressure-volume profiles measured by CardioMEMS monitoring and Daxor's blood volume analysis diagnostic. The CEO stated that Daxor's BVA test provides clinicians with 98% accurate volume measurement, leading to improvements in patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
-
Rhea-AI Summary
Daxor Corporation has been awarded a $1.1 million contract by the United States Defense Health Agency to add electronic medical record integration to its blood volume analyzer. This is the fifth contract awarded to Daxor for the development of their next generation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none

FAQ

What is the current stock price of Daxor Corporation (DXR)?

The current stock price of Daxor Corporation (DXR) is $7.95 as of December 24, 2024.

What is the market cap of Daxor Corporation (DXR)?

The market cap of Daxor Corporation (DXR) is approximately 38.5M.

What does Daxor Corporation specialize in?

Daxor Corporation specializes in medical instrumentation and biotechnology, with a focus on precise blood volume measurement using their BVA-100 system.

What is the BVA-100?

The BVA-100 is a Blood Volume Analyzer, the first FDA-cleared diagnostic tool that provides accurate quantification of blood volume and composition.

How has the BVA-100 improved blood volume measurement?

The BVA-100 provides quick, accurate, and reliable blood volume measurements, overcoming the lengthy and inaccurate traditional methods.

What are some recent achievements of Daxor Corporation?

Recent achievements include the development of the next generation Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes.

How has Daxor performed financially in early 2024?

Daxor reported a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months year-on-year.

Who is the Investor Relations Contact at Daxor Corporation?

Bret Shapiro, the Senior Managing Partner at CORE IR, is the Investor Relations Contact for Daxor Corporation.

What kind of medical events does Daxor participate in?

Daxor participates in significant medical events like the Premier Event for Cardiovascular Industry Leaders and Clinicians.

Where has Daxor Corporation published its research findings?

Daxor has presented data at the American College of Cardiology Scientific Sessions and published research in the American Heart Journal.

What is the significance of the BVA-100 in medical practice?

The BVA-100 provides physicians with accurate blood volume data, improving diagnosis and treatment in various medical and surgical situations.

Where is Daxor Corporation headquartered?

Daxor Corporation is headquartered in New York.

Daxor Corporation

Nasdaq:DXR

DXR Rankings

DXR Stock Data

38.48M
2.03M
56.52%
1.94%
0.13%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK